Evotec - Research never stops
  • Loading...

Overview of Product development partnerships

Evotec's clinical programmes are almost exclusively developed in partnerships with pharmaceutical companies. 

Partner Indication Status Next milestone
Teva/Andromeda Type 1 diabetes DiaPep277, synthetic peptide modulator Phase III Phase II data 2012
Roche Alzheimer's Disease MAO-B inhibitor Phase II Phase IIb start in 2012
JingXin Insomnia EVT 201, GabaA Phase II Clinical start in China 2011
Boehringer Ingelheim Pain not named Phase I Phase I
Pfizer Pain TRPV1 antagonist Phase I /Preclinical First Phase I stopped, back-up in preparation
Animal Health company (undisclosed) Inflammatory diseases EVT 401 Phase I / II Phase II start in 2012

Development partnerships

Roche: MAO-B inhibitor against Alzheimer’s disease

- read more

Andromeda / Teva: DiaPep277

Development partnership with Andromeda on DiaPep277

- read more

Jingxin Pharma: EVT 201

GABAA Receptor Partial Positive Allosteric Modulator- Insomnia

- read more

EVT 401 - P2X7-Antagonist

In August 2011 Evotec partners P2X7 antagonist programme, EVT 401, to a top tier global animal health company

- read more

Boehringer Ingelheim

Multi-year drug discovery collaboration with Boehringer Ingelheim to jointly identify and develop preclinical development candidates for the treatment of various diseases

- read more

Pfizer: TRPV1 antagonist

VR1 antagonist program

- read more